OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Paul on the Future of CAR T-Cell Therapy in Multiple Myeloma Treatment

October 18th 2022

Barry Paul, MD, discusses the emerging benefits of integrating CAR T-cell therapy into treatment paradigms for patients with relapsed/refractory multiple myeloma.

Dr. Jain on the Benefit of CDK7 Inhibitors in HR+ Breast Cancers

October 18th 2022

Amit Jain, MD, discusses the benefit of CDK7 inhibitors in hormone receptor–positive breast cancers.

Dr. Awan on the Evolution of Treating Frontline CLL

October 18th 2022

Farrukh Awan, MD, discusses the evolution of treating frontline chronic lymphocytic leukemia.

Dr. Gupta on the Investigation of Cabozantinib Plus Avelumab in Metastatic Urothelial Cancer

October 18th 2022

Shilpa Gupta, MD, discusses the addition of cabozantinib to avelumab in locally advanced or metastatic urothelial cancer.

Dr. Yorio on the Safety of Targeted Therapies in BRAF-Mutated Melanoma

October 18th 2022

Jeff Yorio, MD, discusses adverse effects associated with targeted agents and combinations in BRAF-mutated melanoma.

Dr. Mascarenhas on the Potential Clinical Significance of Pacritinib in Myelofibrosis

October 18th 2022

John O. Mascarenhas, MD, discusses the potential clinical significance of pacritinib in patients with myelofibrosis.

Dr. Shallis on the Investigation of Uproleselan in AML

October 18th 2022

Rory Shallis, MD, discusses the investigation of uproleselan in acute myeloid leukemia.

Dr. Abou-Alfa on Analyzing Disease Factors to Inform Clinical Decisions in HCC

October 18th 2022

Ghassan K. Abou-Alfa, MD, discusses the analysis of disease and patient factors to inform clinical decisions in hepatocellular carcinoma.

Dr. Goff on Leveraging Clinical Trial Information to Inform Treatment Decisions in HCC

October 18th 2022

Laura Goff, MD, discusses how to consider clinical trial information to inform treatment decisions in patients with hepatocellular carcinoma.

Dr. Karlan on Current Research Evaluating PARP Inhibitor Combination Therapy in Ovarian Cancer

October 18th 2022

Beth Y. Karlan, MD, discusses the current landscape of research investigating the efficacy of PARP inhibitor combination therapies for the treatment of patients with ovarian cancer.

Dr. Iams on Small Cell Lung Cancer Subtyping in Clinical Practice

October 17th 2022

Wade T. Iams, MD, discusses the potential for providing small cell lung cancer subtyping in clinical practice.

Dr. Atrash on the Evolution of BCMA-Directed Therapies in Multiple Myeloma

October 17th 2022

Shebli Atrash, MD, discusses the development and current use of BCMA-targeted antibody-drug conjugates and CAR T-cell therapies for the treatment of patients with multiple myeloma.

Dr. Xu on Future Developments in Kidney Cancer

October 17th 2022

Wenxin Xu, MD, discusses future considerations for the treatment of patients with kidney cancer.

Dr. Goy on Discrepancies in Clinical Trial vs Real-World MCL Treatment

October 17th 2022

Andre H. Goy, MD, discusses clinical trial vs real-world treatments in patients with mantle cell lymphoma.

Dr. Bhalla on Unmet Needs in the Treatment of EGFR Exon 20–Mutant NSCLC

October 17th 2022

Sheena Bhalla, MD, discusses the need for improved understanding of EGFR exon 20 insertion mutations in the development of non–small cell lung cancer treatment.

Dr. Strickler on the Benefit of Combining Tucatinib With Trastuzumab in HER2+ CRC

October 14th 2022

John H. Strickler, MD, discusses the benefit of combining tucatinib with trastuzumab in HER2-positive metastatic colorectal cancer.

Dr. Shore on Future Clinical Research Focuses in Prostate Cancer

October 14th 2022

Neal Shore MD, FACS, discusses future clinical research focuses in prostate cancer.

Dr. Ryan on the Efficacy of Ibrutinib Plus Obinutuzumab in Relapsed/Refractory CLL

October 14th 2022

Christine Ryan, MD, discusses the significance of data for ibrutinib plus obinutuzumab in relapsed/refractory chronic lymphocytic leukemia.

Dr. Kalinsky on Chemotherapy for Premenopausal Patients With HR+/HER2- Breast Cancer

October 13th 2022

Kevin Kalinsky, MD, MS, discusses the role of chemotherapy with ovarian function suppression and hormonal therapy for premenopausal patients with HR–positive/HER2-negative breast cancer.

Dr. Yorio on Treatment Combinations in BRAF-Mutated Melanoma

October 13th 2022

Jeff Yorio, MD, discusses treatment combinations in BRAF-mutated melanoma.